Metadata Automation DREAM Challenge
Open Phase: Ends 2/9/2020
Leaderboard Phase Round 1: 2/10/2020 - 3/9/2020
Leaderboard Phase Round 2: 3/10/2020 - 4/9/2020
Validation Phase: 4/10/2020 - 4/24/2020
Winners Announced: early May 2020
We aim to significantly lower the burden of adding coherent metadata annotations across the data ecosystem to streamline and enable both retrospective harmonization as well as data query, discovery and interpretation. This challenge addresses this time-consuming task with automated metadata annotation of structured data.
CTD^2 Beat AML DREAM Challenge
Open Phase: Ends 1/6/2020
Webinar: 1/6/2020 11:00 AM PST
Leaderboard Phase: 1/6/2020 - 3/2/2020
Validation Phase: 3/2/2020 - 3/16/2020
Winners Announced: 3/23/2020
The goal of the Beat AML DREAM Challenge is to define patient subpopulations tailored to individual treatments by discovering (genomic and transcriptomic) biomarkers of drug sensitivity, as evaluated on an unpublished cohort of patients from the BeatAML project.
CTD^2 Pancancer Drug Activity
Launched: December 2, 2019 (Now Open)
Leaderboard Closes: January 31, 2020
Final Submissions: February 13, 2020
Winners announced: 2-3 weeks after Final Submission
Over the last two years, the Columbia CTD2 Center developed PANACEA (Pancancer Analysis of Chemical Entity Activity), a comprehensive repertoire of dose response curves and molecular profiles representative of cellular responses to drug perturbations. PANACEA covers a broad spectrum of cellular contexts representative of poor outcome malignancies, including rare ones such as GIST sarcoma and gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The goal of the CTD2 Pancancer Drug Activity DREAM Challenge is to foster the development and benchmarking of algorithms to predict targets of chemotherapeutic compounds from post-treatment transcriptional data.
RA2 DREAM Challenge
Launch: November 4, 2019 (Now open)
Final Submissions: May 31, 2020
Winners Announced: July 31, 2020
Rheumatoid Arthritis (RA) is a debilitating disease that causes joint damage in the hands and feet due to inflammation. Accurate measuring of joint damage and progression of disease is essential in assessing the severity of disease, along with being able to monitor patient response to treatment. Scoring of X-ray images is tedious and there can be a great deal of variability between rheumatologists when applying scoring methods. We will leverage nearly 1000 images across a range of disease severities to challenge participants to develop an automated scoring algorithm with the goal of making clinical scoring fast and consistent; this will aid rheumatologists in making the best decisions for patients.
Allen Institute Cell Lineage Reconstruction DREAM Challenge
Registration Opens: September, 2019
Launch: Mid-October, 2019 (Now Open)
Final Submissions: January, 2020
Winners Announced: March, 2020
CRISPR-based molecular tools allow the reconstruction of cell lineages based on the phylogenetic analysis of DNA mutations induced by CRISPR during development. The challenge - a partnership between The Allen Institute and DREAM - will comprise 3 subchallenges focused on reconstructing cell lineage trees of different sizes and nature. Through the usage for training purposes of experimental and in silico generated data sets, the goal of this challenge is to mobilize a larger community for evaluating new optimal tree-building methods.
Designed and run by a community of researchers from a variety of organizations, DREAM Challenges invite participants to propose solutions to fundamental biomedical questions — fostering collaboration and building communities in the process. Sage Bionetworks provides the expertise and infrastructure to host challenges via their Synapse platform. Together, we share a vision allowing individuals and groups to collaborate openly so that the “wisdom of the crowd” provides the greatest impact on science and human health.
If you have an idea for a DREAM challenge, please contact us here.